Sign in

You're signed outSign in or to get full access.

SB

ServisFirst Bancshares, Inc. (SFBS)·Q1 2025 Earnings Summary

Executive Summary

  • Q1 2025 delivered solid fundamentals: EPS was $1.16 (up 26% YoY) on strong deposit (+$886M) and loan (+$281M) growth; PPNR rose 31% YoY while efficiency improved to 35.0% .
  • Against S&P Global consensus, EPS was a slight miss (actual $1.16 vs $1.18*) and S&P “Revenue” was below ($125.2M* vs $134.1M*); management cited fewer days in the quarter, a higher effective tax rate (20% vs ~18% in 2024), and elevated cash at the Fed that diluted NIM by ~6 bps as near‑term headwinds .
  • Credit normalized: NPAs/Assets rose to 0.40% and annualized NCOs to 19 bps, driven by previously impaired, individually evaluated credits; ACL/Loans eased to 1.28% with hurricane reserve release, but dollar ACL increased .
  • Liquidity and capital remained strong (cash $3.35B; CET1 11.48%); deposit growth skewed to municipal and correspondent balances that management expects to seasonally run down, a potential NIM tailwind as cash normalizes .
  • 2025 setup: OpEx guided to ~$46.0–$46.5M per quarter and tax rate ~20%; asset repricing pipeline (>$1.9B over 12 months) and fixed‑rate run‑off (weighted ~4.76%) provide earnings levers alongside steady loan demand; new Chief Credit Officer appointed .

What Went Well and What Went Wrong

  • What Went Well

    • PPNR strength and expense discipline: PPNR reached ~$85.7M and efficiency ratio improved to 34.97%; CFO: “This resulted in an efficiency ratio below 35%, which we are very proud of.”
    • Robust balance sheet momentum: Ending deposits +$886M QoQ (26% annualized) and loans +$281M QoQ (9% annualized), with liquidity of $3.35B and CET1 at 11.48% .
    • Healthy growth outlook and market expansion: “Loan pipeline is up 10% from January… we continue to look at new market expansions in the Southeast.” .
  • What Went Wrong

    • NIM percentage diluted by excess cash: CFO quantified ~6 bps dilution from elevated Fed cash in Q1; loan yields also declined QoQ (6.28% vs 6.43% in Q4) .
    • Credit normalization: NPAs/Assets increased to 0.40% (from 0.26% in Q4), annualized NCOs to 0.19% (vs 0.09% in Q4), tied to previously impaired, individually analyzed loans; two relationships (real estate‑secured, medical‑related) drove much of NPA uptick .
    • Noninterest income down YoY on BOLI compare and seasonal softness: Noninterest income fell 7% YoY, with prior‑year BOLI death benefit driving the comp; mortgage and card were seasonally softer vs Q4 .

Financial Results

Income and margin snapshot

MetricQ3 2024Q4 2024Q1 2025
Net Interest Income ($M)$115.121 $123.168 $123.553
Non-Interest Income ($M)$8.549 $8.803 $8.277
Provision for Credit Losses ($M)$5.659 $5.704 $6.630
Net Income ($M)$59.907 $65.173 $63.224
Diluted EPS ($)$1.10 $1.19 $1.16
Net Interest Margin (%)2.84% 2.96% 2.92%
ROAA (%)1.43% 1.52% 1.45%
ROACE (%)15.55% 16.29% 15.63%
Efficiency Ratio (%)36.90% 35.54% 34.97%

Balance and capital

MetricQ3 2024Q4 2024Q1 2025
Loans (end, $B)$12.338 $12.606 $12.887
Deposits (end, $B)$13.147 $13.543 $14.429
Noninterest DDA (end, $B)$2.576 $2.620 $2.648
CET1 (%)11.25% 11.42% 11.48%
TCE/TA (%)9.47% 9.25% 8.89%

Yield and rate KPIs

MetricQ4 2024Q1 2025
Loan Yields (%)6.43% 6.28%
Investment Yields (%)3.49% 3.31%
Avg Rate on Interest‑Bearing Deposits (%)3.63% 3.40%
NIM – Final Month of Quarter (%)2.95% 2.86%
Cost of Interest‑Bearing Deposits (qtr‑end, %)3.44% 3.42%

Loans by type (end of period)

Category ($M)Q4 2024Q1 2025
Commercial, financial & agricultural$2,869.9 $2,924.5
Real estate – construction$1,489.3 $1,599.4
Owner‑occupied commercial mortgage$2,547.1 $2,543.8
1–4 family mortgage$1,444.6 $1,494.2
Non‑owner occupied commercial mortgage$4,181.2 $4,259.6
Subtotal – real estate mortgage$8,173.0 $8,297.6
Consumer$73.6 $65.3
Total loans$12,605.8 $12,886.8

Credit metrics

MetricQ4 2024Q1 2025
NPAs / Assets (%)0.26% 0.40%
NCOs (annualized) / Avg Loans (%)0.09% 0.19%
ACL / Loans (%)1.30% 1.28%
Provision for Credit Losses ($M)$5.70 $6.63

Versus estimates (S&P Global definitions)

Metric (Q1 2025)ConsensusActualSurprise
Diluted EPS ($)1.18*1.16 -$0.02
S&P “Revenue” ($M)134.10*125.20*-$8.90

Note: For banks, S&P “Revenue” can differ from company “net interest income + noninterest income” (company total was $131.83M) .
Values with asterisks are retrieved from S&P Global.

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Noninterest Expense (OpEx)2025 (quarterly)Core run‑rate ~$45.3M/quarter (Q4 commentary) ~$46.0–$46.5M/quarter Raised
Effective Tax Rate2025~19% run‑rate (Q4) ~20% expected run‑rate Raised
Net Interest MarginNear termDecember margin ~3% ex excess cash; expansion in Q4 Q1 diluted by ~6 bps from elevated Fed cash; cash balances already retracting, aiding NIM Modest improvement expected as liquidity normalizes
Loan Growth2025“Normalize over 2025” (mixed 2024 cadence) “Low double digits could be a good pace” Positive bias
Asset RepricingNext 12 months~1.8B repricing pipeline discussed in Q4 ~$1.5B fixed at ~4.76% + ~$100M MBS at ~2.5%; ~$2.2B variable repricing at ~7.52% Reinforced visibility

Earnings Call Themes & Trends

TopicPrevious Mentions (Q3 2024)Previous Mentions (Q4 2024)Current Period (Q1 2025)Trend
Liquidity/NIMNIM 2.84%; cash built through 2H NIM up to 2.96%; Dec near ~3% ex excess cash NIM 2.92%; diluted ~6 bps by elevated Fed cash; cash beginning to retract Improving as cash normalizes
Deposit mixEnding deposits $13.15B; mix stable Deposit growth QoQ; correspondent funding strong Large QoQ inflow ($886M) skewed to municipal/correspondent; expected seasonal runoff Seasonal runoff expected
Loan growth/pipelineLoans $12.34B; uneven 2024 cadence Pipeline up; fixed‑rate repricing runway 9% annualized growth; pipeline +10% from Jan; low‑double‑digit pace plausible Gradual acceleration
Credit qualityNPAs/Assets ~0.25% NPAs/Assets 0.26%; NCOs 9 bps; ACL 1.30% NPAs/Assets 0.40%; NCOs 19 bps; ACL 1.28% (dollar ACL up); two medical‑related relationships Normalizing from troughs
Expenses/efficiencyEfficiency 36.9% Efficiency 35.54%; core expense commentary Efficiency 34.97%; OpEx guide $46–$46.5M/quarter Best‑in‑class, disciplined
Expansion/hiringNew markets progressing (Memphis, Auburn) Added producers; opportunistic hiring strategy 4 new producers in Q1; exploring new markets; new CCO appointed Continued investment

Management Commentary

  • Strategy and growth: “With our strong balance sheet, we are looking at opportunities for new and expanded customer relationships and we continue to look at new market expansions in the Southeast.” — Tom Broughton, CEO .
  • Quarter drivers: “We reported net income of $63.2 million, diluted EPS of $1.16 and pre‑provision net revenue of $85.7 million… The margin percent is diluted this quarter by our higher‑than‑normal cash balances at the Fed… diluted our margin by 6 basis points this quarter.” — David Sparacio, CFO .
  • Credit tone: “Charge‑offs were… 19 basis points… more in line with pre‑COVID benchmarks… two relationships… both real estate secured.” — Henry Abbott, CCO .
  • Deposit outlook/NIM path: “Municipal deposits will probably run down… We’re already seeing [cash balances] come down… expect cash balances to come down over the next few months.” — Management .
  • Operating framework: “For the remainder of the year, we expect our noninterest expense to be in $46 million to $46.5 million… our effective tax rate… about 20%… expected run rate for the remainder of 2025.” — CFO .

Q&A Highlights

  • Deposits and NIM trajectory: Seasonal normalization of municipal/correspondent inflows should reduce cash at the Fed, supporting NIM; management is already seeing cash balances retrace .
  • Loan growth and pricing: Low‑double‑digit loan growth is plausible; new originations around high‑6s yields; pricing “already too tight,” but steady; mix roughly even fixed/variable in new production .
  • OpEx guide and hiring: OpEx guided to $46–$46.5M per quarter before incremental hires tied to expansion; hiring remains opportunistic .
  • NPA color: Two medical‑related, real‑estate‑secured relationships (one a hospital, one a physician with strong collateral) drove most of the NPA increase .
  • Repricing runway: ~$900M fixed repricing in ≤12 months at ~4.76%; ~$2.2B variable repricing at ~7.52%; ~$100M MBS paydowns at ~2.5% .

Estimates Context

  • Q1 2025 vs S&P Global consensus: EPS $1.16 vs $1.18* (slight miss); S&P “Revenue” $125.2M* vs $134.1M* (miss). Company “net interest income + noninterest income” totaled $131.83M, which differs from S&P’s bank revenue definition .
  • Implications: Fewer days in Q1 vs Q4, higher effective tax rate (20%), and elevated cash balances at the Fed (~6 bps NIM dilution) explain the small EPS shortfall; as seasonal deposits recede and cash normalizes, NIM should benefit .

Values with asterisks are retrieved from S&P Global.

Key Takeaways for Investors

  • Core profitability is improving: PPNR up ~31% YoY with efficiency ~35%, underscoring controllable expense momentum even as the rate backdrop evolves .
  • Near‑term NIM recovery levers: Seasonal runoff of higher‑cost municipal/correspondent deposits and lower excess cash should support margin; management is already seeing balances retrace .
  • Visible asset repricing pipeline: ~$1.5B fixed (~4.76%) and ~$2.2B variable (~7.52%) repricing within 12 months, plus ~$100M MBS at ~2.5%—a constructive backdrop for earnings as pricing resets .
  • Credit normalizing from benign levels: Higher NPAs and NCOs reflect specific, collateralized relationships and previously impaired credits; ACL/Loans at 1.28% with dollar ACL up supports resilience .
  • 2025 guideposts: OpEx ~$46–$46.5M/quarter and ~20% tax rate set the baseline; consistent loan demand and disciplined pricing remain key to delivering mid‑teens ROE .
  • Capital/liquidity remain strengths: CET1 11.48% and on‑balance‑sheet cash of $3.35B (18% of assets) provide flexibility to pursue growth and manage NIM .
  • Organizational depth: Appointment of a new Chief Credit Officer (Jim Harper) supports ongoing growth with prudent credit oversight during a credit normalization phase .

Appendix: Additional Data Points

  • Deposit and loan growth QoQ: Deposits +$885.6M (26.3% annualized); Loans +$281.0M (9.0% annualized) .
  • Company “total revenue” proxy (NII + noninterest income): $131.83M .
  • CET1, Total capital: 11.48% and 12.93%, respectively .